Introduction
Bomac can trace it’s roots to 1958 when it was established as an Animal Health company, importing finished product from USA and Europe to sell to local Veterinarians.  The business quickly expanded into local product development and manufacture.  A strong commitment to Research and Development now ensures a continuous supply of products, all manufactured competitively in New Zealand. Bomac has since been acquired by Bayer and thus Bomac is now a Bayer Company.

NZ
In it’s local market Bomac has the widest portfolio of any company and although all Multinational companies are present in the market, Bomac holds a substantial market share.  In New Zealand there are over 5M Dairy cows (double the number of Australia and more than half the entire USA population) 40M Sheep, 4M Beef cattle, 2M Deer and a pig, poultry and Companion Animal market, including a substantial equine population.  All this and just 4M People confirms New Zealand’s substantial reliance on its Agricultural sector, with Dairy, Beef and sheep being the countries top 3 export categories.

As a strong local Animal Health Company Bomac is  respected and relied upon to develop innovative products to support this important Sector

Export
Bomac product now reaches over 70 countries as shown in the Distributor map.  Many long term, loyal and dedicated Distributors have worked tirelessly with Support from Bomac, to popularise the products across the planet. 

Australia is Bomac’s nearest neighbour and understandably largest Export Customer.  Bomac has its own Company there and more than 170 products are approved and enjoying market success.  The Company is based in Sydney and supplies products for almost all species.

The Far East is well developed from Japan and Korea, south to Taiwan and Philippines, Vietnam, Malaysia and Indonesia are all markets where the Bomac Brand is well known.

Bomac is particularly strong in the Middle East due to strong support from its powerful Distributors.  Some products are specially developed for the market and almost every Pharmacy across the region will be stocking a Bomac product of some type.

Southern Africa is also supplied but Bomac sees more potential within the African Continent. Expansion plans to further penetrate the markets in Central and Latin America are also underway.

Bomac has a wide range of products and looks to find
strong distributors for each product category in the regions.  Although Bomac’s export business is already substantial it is looking to build further on its established business, by developing more products to suit each market and by finding distributors where gaps exist. More promotional and exhibition support is also envisaged.

Manufacturing
Bomac has 3 manufacturing facilities on one site in Auckland, New Zealand.

The core technology related to Injectable formulations and delivery systems. From large volume intravenous parenterals to small volume single dose vials, Bomac has an extensive range of products from this facility.  Bomac also has competency in manufacturing liquid products, solutions, suspensions, creams, ointments and emulsions for oral or topical to transdermal products for a wide range of species.  The third facility manufactures powder based products

QA/QC
Across all manufacturing, indeed all Bomac processes, is a comprehensive GMP system to international standards.  Bomac is approved to supply the Europe Union as well as satisfactorily passed many audits from foreign regulators and customers the all over the world.  A large team maintains an extensive QA program including validation of processes and Maintenance.  All this ensures the Bomac reputation for quality is intact and will continue to meet international Standards

R&D
A key factor to the success of Bomac has been its relentless investment in R&D to develop innovative products to satisfy and exceed the demands of Veterinarians and end users in New Zealand and around the world through its various distributors.